Decera Clinical Insights

In this podcast, we examine the rise of viral “blips” in the era of highly sensitive HIV assays. As testing now detects viral loads down to 20 copies/mL, clinicians are increasingly faced with low-level detectable results that are often benign rather than signs of virologic failure. We discuss how to distinguish transient assay “noise” from persistent low-level viremia, review key guideline thresholds, and share practical strategies for follow-up and patient reassurance. Learn how clear, evidence-based communication can reduce unnecessary anxiety, avoid premature treatment changes, and support confidence in sustained viral suppression.

Get access to all of our new podcasts by subscribing to the Decera Clinical Insights Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Segment 2: Discussion on the operational and logistics aspects of integrating rapid point-of-care testing into clinical workflows.

Get access to all of our new podcasts by subscribing to the Decera Clinical Insights Podcast show on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Segment 1: Discussion on the clinical and patient-experience benefits of rapid point-of-care testing for sexually transmitted infections.

Get access to all of our new podcasts by subscribing to the Decera Clinical Insights Podcast show on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Presenter:

Philip R. Muskin MD, MA, DLFAPA
Professor of Psychiatry
Columbia University Irving Medical Center
Senior Consultant in Consultation-Liaison Psychiatry
New York-Presbyterian Hospital
New York, NY

Chronic medical illnesses such as cancer are characterized by a notably increased prevalence of depression. Furthermore, several challenges may arise in managing the depression in these patients, given their anti-cancer regimens. Here, we present a short learning module that will help clinicians better recognize and diagnose patients with cancer who may also have depression, as well as develop treatment plans tailored to their concomitant anti-cancer regimens.

Follow along with the slideset located here:
https://bit.ly/3Auicb2 

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Presenter:

Hope S. Rugo MD
Professor of Medicine
University of California
San Francisco Comprehensive Cancer Center

TNBC comprises approximately 15% of newly diagnosed breast cancer cases and is defined by being estrogen-receptor negative, progesterone-receptor negative, and human epidermal growth factor receptor 2-negative. This breast cancer subtype is very aggressive, with a median overall survival slightly greater than 1 year. Furthermore, treatment options are limited. New and innovative therapies are being evaluated in patients to improve their outcomes, including progression-free survival and time to deterioration in health-related quality of life. Here, we present an expert-led review on current standards of care, as well as novel and emerging treatment regimens that are in the pipeline for approval by the United States Food and Drug Administration and/or under investigation.

Follow along with the slideset located here:
https://bit.ly/3krD3Gj 

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Presenter:

Gail J. Roboz MD
Professor of Medicine
Director, Clinical and Translational Leukemia Program
Weill Medical College of Cornell University
New York-Presbyterian Hospital
New York, New York, United States

This brief program will begin with a review of NCCN Guidelines® Recommendations for the treatment of AML in individuals 60 years of age or older. Next, the results of the BRIGHT AML 1003 trial comparing glasdegib + LDAC to LDAC alone, the VIALE-A trial comparing venetoclax + azacitidine vs azacitidine alone, and a comparison of CPX-351 vs standard of care cytarabine + daunorubicin (7 + 3 regimen) for induction and consolidation, will be reviewed. The faculty will discuss FLT3 and IDH inhibitor approvals for AML, IDK differentiation syndrome, and measuring MRD in AML. Finally, results of a trial examining oral azacitidine and a meta-analysis of 5 trials examining gemtuzumab ozogamicin will be reviewed.https://www.clinical-care.org/resource-center-details/using-available-evidence-and-guidelines-for-managing-an-evolving-aml-treatment-paradigm

Follow along with the slideset located here:
https://bit.ly/3lJNHYC  

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.